Evidence map›Paper›PMID 31809917›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020

New-Onset Diabetes, Longitudinal Trends in Metabolic Markers, and Risk of Pancreatic Cancer in a Heterogeneous Population.

Brian Z Huang, Stephen J Pandol, Christie Y Jeon, Suresh T Chari, Catherine A Sugar, Chun R Chao, Zuo-Feng Zhang, Bechien U Wu, Veronica Wendy Setiawan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Brian Z HuangDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California; Department of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: brian.huang@kp.org.
Stephen J PandolDivision of Gastroenterology, Department of Medicine, Cedars-Sinai Medical Center and Department of Veterans Affairs, Los Angeles, California.
Christie Y JeonSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Suresh T ChariDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
Catherine A SugarDepartment of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Chun R ChaoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
Zuo-Feng ZhangDepartment of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California.
Bechien U WuCenter for Pancreatic Care, Division of Gastroenterology, Kaiser Permanente, Los Angeles, California.
Veronica Wendy SetiawanDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California; Norris Comprehensive Cancer Center, Los Angeles, California.
Cedars-Sinai Medical Center · USKaiser Permanente · USUniversity of California, Los Angeles · USUniversity of Southern California · USMayo Clinic · US

Funding

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)U01DK108328 · NIDDK · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Liang Li, Suyu Liu · 2015 to 2026
$32.8M
UCLA CANCER EPIDEMIOLOGY TRAINING PROGRAMT32CA009142 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZHANG, ZUO-FENG · 1986 to 2024
$6.3M
Multidisciplinary Training in Ethnic Diversity and Cancer DisparitiesT32CA229110 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2019 to 2023
$2.1M
Investigating the cause of racial/ethnic disparity in pancreatic cancer incidenceR01CA209798 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SETIAWAN, VERONICA WENDY · 2017 to 2020
$1.8M
NCI NIH HHS R01 CA209798NCI NIH HHS T32 CA009142NCI NIH HHS T32 CA229110NIDDK NIH HHS U01 DK108328
6 · The paper itself

Abstract

BACKGROUND &

aimsObservational studies of predominantly white populations have found new-onset diabetes to be associated with increased risk of pancreatic cancer. We sought to determine whether this relationship applies to other races or ethnicities and to identify metabolic profiles associated with increased risk of pancreatic cancer.

methodsWe conducted a population-based cohort study of Asian, black, Hispanic and white patients from Kaiser Permanente Southern California from 2006 through 2016 (n = 1,499,627). Patients with diabetes were identified based on glucose and hemoglobin A1c (HbA1c) measurements. We used Cox regression to assess the relationship between diabetes status and duration and pancreatic cancer. For patients with recent diagnoses of diabetes (1 year or less) we compared longitudinal changes in glucose, HbA1c, and weight, from time of diabetes diagnosis through 3 years prior to the diagnosis, in patients with vs without pancreatic cancer.

resultsWe identified 2,002 incident cases of pancreatic cancer from nearly 7.5 million person-years of follow-up. Compared to patients without diabetes, individuals who received a recent diagnosis of diabetes had an almost 7-fold increase in risk of pancreatic cancer (relative risk, 6.91; 95% CI, 5.76-8.30). Among patients with a recent diagnosis of diabetes, those who developed pancreatic cancer had more rapid increases in levels of glucose (Δslope: cases, 37.47 mg/dL vs non-cases, 27.68 mg/dL) and HbA1c (Δslope: cases, 1.39% vs non-cases, 0.86%) in the month preceding the diagnosis of diabetes, and subtle weight loss in the prior years (slope: cases -0.18 kg/interval vs non-cases 0.33 kg/interval). These longitudinal changes in markers of metabolism were stronger for specific race and ethnic groups.

conclusionsIn a study of a large ethnically diverse population, we found risk of pancreatic cancer to be increased among patients with a diagnosis of diabetes in the past year among different races and ethnicities. Weight loss and rapid development of poor glycemic control were associated with increased risk of pancreatic cancer in multiple races.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 2Pancreatic NeoplasmsBlood GlucoseCohort StudiesGlycated HemoglobinHumansWhite PeopleBlood GlucoseGlycated HemoglobinObesityPancreasRacial VariationType 2 Diabetes

Identifiers

PMID31809917
PMCPMC7269863
OpenAlexW2992927504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.